copanlisib
Selected indexed studies
- Copanlisib. (, 2012) [PMID:31643732]
- Copanlisib. (, 2006) [PMID:29999999]
- Copanlisib for the treatment of adults with relapsed follicular lymphoma. (Expert Rev Clin Pharmacol, 2020) [PMID:32576028]
_Worker-drafted node — pending editorial review._
Connections
copanlisib is a side effect of
Sources
- Copanlisib. (2012) pubmed
- Copanlisib. (2006) pubmed
- Copanlisib for the treatment of adults with relapsed follicular lymphoma. (2020) pubmed
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. (2021) pubmed
- Copanlisib: First Global Approval. (2017) pubmed
- Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma. (2019) pubmed
- Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma. (2020) pubmed
- Copanlisib in the treatment of non-Hodgkin lymphoma. (2020) pubmed
- Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. (2021) pubmed
- Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. (2018) pubmed